Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 6/20 | 0.69 |
| ▸ | F2 | P00734 | 4/20 | 0.66 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.61 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 5/20 | 0.60 |
| ▸ | CCKBR | P32239 | 2/20 | 0.60 |
| ▸ | GCGR | P47871 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361541 | 0.93 | CALCR (0.70) | CALCRGLP1RGCGR | |
| SCHEMBL30432714 | 0.92 | CALCR (0.67) | CALCRF2CRHR1CRHR2HCRTR1 | |
| SCHEMBL31167610 | 0.91 | CALCR (0.71) | CALCRF2GLP1RGCGR | |
| SCHEMBL30752380 | 0.91 | CALCR (0.71) | CALCRF2GLP1RGCGR | |
| SCHEMBL30752384 | 0.91 | CALCR (0.71) | CALCRGLP1RGCGR | |
| SCHEMBL30607425 | 0.90 | CALCR (0.66) | CALCRF2CRHR1CRHR2HCRTR1 | |
| SCHEMBL30752386 | 0.90 | CALCR (0.69) | CALCRF2GLP1RGCGR | |
| SCHEMBL30752383 | 0.90 | CALCR (0.70) | CALCRHCRTR1HCRTR2GLP1RGCGR | |
| SCHEMBL30432219 | 0.89 | CALCR (0.62) | CALCRF2CRHR1CRHR2HCRTR1 | |
| SCHEMBL30746744 | 0.89 | CALCR (0.58) | CALCRF2CRHR1CRHR2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161447-A | Long-acting insulin analogue, and preparation method and application thereof | 濮阳市旌胜新能源科技有限公司 | 2024-12-20 | — | — | CN | disclosed |